 Home > Biochemistry News > Biotechnology News > Preliminary clinical results of innovative TCR immunotherapy combination for treating melanoma are positive

Preliminary clinical results of innovative TCR immunotherapy combination for treating melanoma are positive

 Last Update: 2021-12-03
 Source: Internet
 Author: User

Tags

ginger immune system

zo 1 antibody

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Immunocore announced that it will demonstrate its T-cell receptor therapy tebentafusp combined with PD-L1 inhibitor durvalumab and/or CTLA4 inhibitor tremelimumab at the 36th annual meeting of the Society for Cancer Immunotherapy (SITC) in the treatment of metastatic skin melanoma (MCM) Phase 1b clinical trial results

Tebentafusp is a bispecific molecule

It is worth noting that the company's corresponding technology allows TCR to recognize cancer antigens in cells with high affinity, which is expected to break through the limitations of existing antibody drugs and increase the number of recognizable targets from 10% to 90%

▲The design of this type of TCR therapy mimics the natural TCR mechanism of action (picture source: Immunocore company official website)

In this phase 1b trial, most patients have previously been treated with anti-PD-1 or PD-L1 inhibitors

Note: The original text has been deleted

Reference materials:

[1] Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.